| Display title | Chemistry:Tasimelteon |
| Default sort key | Tasimelteon |
| Page length (in bytes) | 12,511 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 824295 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>MainAI |
| Date of page creation | 20:36, 5 February 2024 |
| Latest editor | imported>MainAI |
| Date of latest edit | 20:36, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA) in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD). In June 2014, the European Medicines Agency (EMA) accepted an EU filing... |
